New drug tested in people with liver disease
NCT ID NCT05891158
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at how the body handles a single shot of fazirsiran in 34 people with mild, moderate, or severe liver problems, compared to those with healthy livers. Participants were followed for 6 months after the injection. The goal was to measure drug levels and check for side effects, not to treat the liver condition.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATIC IMPAIRMENT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CRU Hungary Kft
Kistarcsa, 2143, Hungary
-
Summit Clinical Research s.r.o.
Bratislava, 851 05, Slovakia
-
Summit Clinical Research s.r.o.
Malacky, Slovakia
-
Summit Clinical Research s.r.o.
Nové Zámky, 940 34, Slovakia